SAN FRANCISCO, June 5, 2025 /PRNewswire/ -- A securities class action lawsuit styled Cockrell v. UroGen Pharma Ltd. et al., No. 3:25-cv-06088 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired UroGen securities between July 27, 2023 and May 15,...
Hence then, the article about urogen pharma ltd urgn faces securities class action amid fda s briefing document and subsequent odac vote against ugn 102 hagens berman was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA's Briefing Document and Subsequent ODAC Vote Against UGN-102- Hagens Berman )
Also on site :
- Teens arrested after large disturbance, multiple fights at Joliet mall
- Transcript: Bank of America CEO Brian Moynihan on "Face the Nation with Margaret Brennan," Dec. 28, 2025
- Feel Free customers say the kratom drink is making them sick. Toothless FDA rules on dietary supplements are helping it remain a bestseller